Access Denied? The Unintended Consequences of Pending Drug Pricing Rules
Abstract
:1. Introduction
2. Pending Regulatory Changes Will Lower the Number of Clinical Trials for New Medications in Canada
3. Fewer Clinical Trials Will Mean Lower Research and Development Investments
4. Pending Changes Will Reduce Patients’ Access to New Medications
5. Concerned Organizations Are Speaking Up
6. Physicians Must Be Heard
Funding
Acknowledgments
Conflicts of Interest
References
- Government of Canada: About the PMPRB Guidelines. Available online: https://www.canada.ca/en/patented-medicine-prices-review/services/legislation/about-guidelines/guidelines.html (accessed on 25 January 2022).
- Fraser Institute: New Regulations Will Ultimately Deprive Canadians of New Medicines. Available online: https://www.fraserinstitute.org/blogs/new-regulations-will-ultimately-deprive-canadians-of-new-medicines (accessed on 18 January 2022).
- Gastrointestinal Society: Patented Medicine Prices Review Board Changes and Their Impact on Canadians, Impact Report. December 2020, p. 11. Available online: https://badgut.org/wp-content/uploads/PMPRB-Impact-Report-2021.pdf (accessed on 28 March 2022).
- Fraser Institute: New Review Rules—The Impact on Drug Access in Canada. Available online: https://www.fraserinstitute.org/blogs/new-review-rules-the-impact-on-drug-access-in-canada (accessed on 13 December 2021).
- Kanavos, P.; Fontrier, A.-M.; Gill, J.; Efthymiadou, O. Does external reference pricing deliver what it promises? Evidence on its impact at national level. Eur. J. Health Econ. 2020, 21, 129–151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Life Sciences Ontario: Impact of PMPRB Pricing Changes—Final Research Report. Available online: https://lifesciencesontario.ca/wp-content/uploads/2020/05/Research-Etc.-PMPRB-Survey-02-03-20.pdf (accessed on 10 December 2021).
- Innovative Medicines Canada. Clinical Trials in Canada: A Pandemic Snapshot. Available online: http://innovativemedicines.ca/clinical-trials-canada-pandemic-snapshot/ (accessed on 10 December 2021).
- Canadian Health Policy Journal. Clinical Trials in Canada Decrease: A Sign of Uncertainty Regarding Changes to the PMPRB? Available online: https://www.canadianhealthpolicy.com/products/clinical-trials-in-canada-decrease--a-sign-of-uncertainty-regarding-changes-to-the-pmprb-.html?buy_type= (accessed on 10 December 2021).
- Samuel, N.; Verma, S. Cross-comparison of cancer drug approvals at three international regulatory agencies. Curr. Oncol. 2016, 23, e454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fraser Institute: Canadians Wait More Than 450 Days Longer for Access to New Medicines Than Americans and Europeans. Available online: https://www.fraserinstitute.org/sites/default/files/timely-access-to-new-pharmaceuticals-in-canada-US-and-EU-newsrelease.pdf (accessed on 9 December 2021).
- Gotfrit, J.; Shin, J.J.; Mallick, R.; Stewart, D.J.; Wheatley-Price, P. Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. Oncologist 2020, 25, e130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- (The Canadian Press) Benefits Canada. Health Canada Delaying New Drug Pricing Regulations Another Six Months. Available online: https://www.benefitscanada.com/news/bencan/health-canada-delaying-new-drug-pricing-regulations-another-six-months/ (accessed on 9 December 2021).
- Liberals Once Again Delay PMPRB Changes to Lower Price of Medicines in Canada; The Canadian Press: Toronto, ON, Canada, 2022; Available online: https://www.benefitscanada.com/benefits/benefits-law/liberals-once-again-delay-pmprb-changes-to-lower-price-of-medicines-in-canada/ (accessed on 9 December 2021).
- Government of Canada: Statement from the Minister of Health. 23 December 2021. Available online: https://www.canada.ca/en/health-canada/news/2021/12/statement-from-the-minister-of-health-on-the-deferral-of-coming-into-force-of-the-regulations-amending-the-patented-medicines-regulations.html (accessed on 29 December 2021).
- Canada Gazette, Part II, Volume 156, Number 1. 5 January 2022. Available online: https://www.gazette.gc.ca/rp-pr/p2/2022/2022-01-05/html/sor-dors273-eng.html (accessed on 9 January 2021).
- Skinner, B.J. Lowering the Price of New Drugs Comes With Too High a Cost—Canadians’ Health. Available online: https://business.financialpost.com/opinion/lowering-the-price-of-new-drugs-comes-with-too-high-a-cost-canadians-health (accessed on 13 December 2021).
Three Major Unintended Consequences of Pending Drug Pricing Rules |
---|
|
|
|
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kaplan, A.; Stewart, D.J.; Batist, G.; Spadafora, S.; Sehdev, S.; Goodman, S.G. Access Denied? The Unintended Consequences of Pending Drug Pricing Rules. Curr. Oncol. 2022, 29, 2504-2508. https://doi.org/10.3390/curroncol29040204
Kaplan A, Stewart DJ, Batist G, Spadafora S, Sehdev S, Goodman SG. Access Denied? The Unintended Consequences of Pending Drug Pricing Rules. Current Oncology. 2022; 29(4):2504-2508. https://doi.org/10.3390/curroncol29040204
Chicago/Turabian StyleKaplan, Alan, David J. Stewart, Gerald Batist, Silvana Spadafora, Sandeep Sehdev, and Shaun G. Goodman. 2022. "Access Denied? The Unintended Consequences of Pending Drug Pricing Rules" Current Oncology 29, no. 4: 2504-2508. https://doi.org/10.3390/curroncol29040204
APA StyleKaplan, A., Stewart, D. J., Batist, G., Spadafora, S., Sehdev, S., & Goodman, S. G. (2022). Access Denied? The Unintended Consequences of Pending Drug Pricing Rules. Current Oncology, 29(4), 2504-2508. https://doi.org/10.3390/curroncol29040204